CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
The procedure, named 'Shetty Test' after its creator, could change the way suspected fractures are treated
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
This facility will design & develop instruments, perform product reliability performance testing and verification
Subscribe To Our Newsletter & Stay Updated
